Gurbel, Paul A. http://orcid.org/0000-0002-5461-568X
Bliden, Kevin
Sherwood, Matthew
Taheri, Hamid
Tehrani, Behnam
Akbari, Marjaneh
Yazdani, Shahram
Asgar, Juzer Ali
Chaudhary, Rahul
Tantry, Udaya S.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study
https://doi.org/10.1007/s11239-020-02205-5
Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory
https://doi.org/10.1007/s11239-024-02953-8
Funding for this research was provided by:
Inova Health System
Article History
Accepted: 19 January 2024
First Online: 13 March 2024
Declarations
:
: Dr. Paul A Gurbel, Dr. Gurbel has received consulting fees and/or honoraria from Bayer, Vectura/Otitopic, Janssen, Cleveland Clinic foundation, Wolters Kluwer Pharma, Web MD Medscape, Baron and Budd, Premier Health Care Resource, Baim Institute, and Medforce; institutional research grants from Accriva Diagnostics, AstraZeneca, Bayer, Cronos, Janssen Pharmaceuticals Inc., Haemonetics, Hikari Dx, Idorisa, Labcorp Drug Development, Novartis, Prolocor, Recor Medical, Vectura Limited, Zoll Medical Corporation; in addition, Dr. Gurbel has two patents, Detection of restenosis risk in patients issued and Assessment of cardiac health and thrombotic risk in a patient. Dr. Gurbel was an expert witness in a lawsuit associated with Plavix. Other authors report no relevant disclosures.